Akero Therapeutics Inc’s recent filing unveils that its Officer Timothy Rolph acquired Company’s shares for reported $2.0 million on May 06 ’25. In the deal valued at $40.00 per share,50,000 shares were bought.
Then, Rolph Timothy sold 6,250 shares, generating $256,438 in total proceeds. Upon selling the shares at $41.03, the Chief Scientific Officer now owns 169,721 shares.
Before that, Yale Catriona sold 9,073 shares. Akero Therapeutics Inc shares valued at $343,962 were divested by the Chief Development Officer at a price of $37.91 per share. As a result of the transaction, Yale Catriona now holds 95,034 shares, worth roughly $3.99 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Tuesday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -6.46% to $42.02. Over the last five days, the stock has lost -2.37%. Akero Therapeutics Inc shares have risen nearly 51.04% since the year began. Nevertheless, the stocks have risen 113.19% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $42.17, while 200 days put it at $34.12.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 40.99, which if violated will result in even more drops to 39.95. On the upside, there is a resistance level at 43.84. A further resistance level may holdings at 45.65. The Relative Strength Index (RSI) on the 14-day chart is 51.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.45, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 44.46%. Stochastics %K at 74.99% indicates the stock is a holding.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
